1.

Introduction
When first diagnosed via transurethral resection of bladder tumor (TURBT), most of bladder cancers (BCa) are Ta-T1 non-muscle-invasive bladder cancers (NMIBCs) according to the tumor, node, and metastasis (TNM) classification system [1, 2] . NMIBCs represent a heterogeneous category of tumors associated with, depending on the risk profile, high recurrence (30-80%) and progression (25-50%) rates, and leading to cancer death after bladder-sparing treatment within 5 yr in about 16-23% of cases [3] . In contrast, patients with high-grade (HG) muscle-invasive bladder cancers (MIBCs) are at a significant risk of developing metastatic disease, with a 5-yr overall survival (OS) rate of 68% after radical cystectomy (RC) for patients with pathologically organ-confined BCa (pT2), compared with 25-30% for those with extravesical extension [4, 5] .
Surgical management of NMIBC and MIBC tumors are therefore completely different, with initial TURBT being the first diagnostic and therapeutic procedure for NMIBC and only a diagnostic procedure for MIBC patients suitable for RC [6, 7] . Notably, TURBT is operator dependent; therefore, presence of residual disease (reflecting incomplete BCa resection) varies widely with operators' experience, increasing recurrence rates, progression, and finally cancerrelated death [8, 9] . About 7-30% of NMIBCs are understaged after TURBT, increasing up to 45% when resection does not include detrusor muscle [10, 11] . Based on these issues, European Association of Urology guidelines recommend a second look and resection (repeated TURBT [Re-TURBT]) 2-6 wk following primary TURBT for all T1 tumors as well as for those in which no detrusor muscle in the specimen was included [12] .
Multiparametric magnetic resonance imaging (mpMRI) for BCa is expanding and becoming increasingly accurate in providing high tissue contrast resolution, being able to finely differentiate bladder wall layers [13, 14] . In particular, recent retrospective experience reported promising outcomes implementing Vesical Imaging Reporting and Data System (VI-RADS) score previously described [15] , which was demonstrated to be a reliable image-guided approach to assess the presence of muscle invasiveness in the pre-TURBT setting [16] .
The aim of this study was to validate the diagnostic accuracy of VI-RADS scoring system in discriminating NMIBC from MIBC in a large prospective single-center cohort of patients who underwent mpMRI of the bladder as an initial diagnostic tool before TURBT.
As the secondary endpoint, we aimed to verify, specifically for HR-NMIBC category, potential clinical application of VI-RADS score as a predictor of adverse pathology at Re-TURBT in order to investigate the performance of mpMRI for the selection of patients who could potentially avoid unnecessary Re-TURBT, and on the contrary, to detect those at higher risk for understaged disease after primary resection who should not miss Re-TURBT.
2.
Patients and methods
Patient population and study design
This prospective study received formal Institutional Review Board and Ethical Committee approval. The study was conducted in line with the European Urology and Good Clinical Practice guidelines accordingly to ethical principles laid down by the latest version of the Declaration of Helsinki. Written informed consent was obtained for all patients enrolled in the study. Between December 2017 and May 2019, all patients referred to our institutions for BCa suspicion were offered mpMRI before TURBT as per institution protocol. Patients with contraindications to perform mpMRI were excluded (ie, patients with impaired renal function; patients with claustrophobic disorder, with MR "unsafe" or "conditional" devices; and those who could not attain adequate bladder distension).
Each patient underwent mpMRI of the bladder to evaluate diagnostic accuracy of VI-RADS score in discrimination between NMIBC and MIBC at initial TURBT. According to secondary endpoint, following TURBT, patients diagnosed with low-risk NMIBC (LR-NMIBC), primary initial TURBT of 91.9% (95% confidence interval [CI]: 82.2-97.3), 91.1% (95% CI: 85.8-94.9), 77.5% (95% CI: 65.8-86.7), and 97.1% (95% CI: 93.3-99.1), respectively. The area under the curve (AUC) was 0.94 (95% CI: 0.91-0.97). Among HR-NMIBC patients (n = 114), mpMRI before TURBT showed sensitivity, specificity, PPV, and NPV of 85% (95% CI: 62.1-96.8), 93.6% (95% CI: 86.6-97.6), 74.5% (95% CI: 52.4-90.1), and 96.6% (95% CI: 90.5-99.3) respectively, to identify patients with MIBC at Re-TURBT. The AUC was 0.93 (95% CI: 0.87-0.97). Conclusions: VI-RADS is accurate for discriminating between NMIBC and MIBC. Within HR-NMIBC cases, VI-RADS could, in future, improve the selection of patients who are candidate for Re-TURBT. Patient summary: We investigated the accuracy of Vesical Imaging Reporting and Data System (VI-RADS) score to asses bladder cancer staging before transurethral resection of bladder tumors, and we explored the performance of VI-RADS score as a future preoperative predictive tool for the selection of high-risk non-muscle-invasive bladder cancer patients who are candidate for undergoing early repeated transurethral resection of the primary tumor site. and/or concomitant carcinoma in situ (CIS), MIBC, and nonurothelial bladder carcinoma were excluded from this secondary-aim analysis. All patients selected for undergoing Re-TURBT due to high-risk Ta-T1 NMIBC were further evaluated to assess the level of concordance between Re-TURBT outcomes and preoperatively determined VI-RADS scores. The study design is summarized in Fig. 1 .
Imaging acquisition protocol
All patients underwent the same mpMRI protocol at 3 Tesla scan (Discovery 750; GE, Italy). According to VI-RADS [15] , T2-weighted sequences were acquired in axial, coronal, and sagittal planes; diffusion-weighted images were acquired in axial plane with high b values (b = 0-800-1000, up to 2000s/mm 2 ), and dynamic contrast-enhanced images were acquired in axial plane with a temporal resolution of 5 s. Imaging parameters and VI-RADS scoring flowchart are summarized in Supplementary Table 1 and Supplementary  Fig. 1 . Patients were administered an intramuscular antispasmodic agent and instructed to drink 500-1000 ml of water 30 min before the examination to obtain adequate bladder distension. All examinations were reviewed by two urogenital radiologists, blinded to clinical [ ( F i g . _ 1 ) T D $ F I G ] history. Both readers assigned a VI-RADS score (1-5) to each lesion (up to 3 per patient), and for each patient, only the one with the highest VI-RADS score was considered. A VI-RADS cutoff score of 3 to define MIBC was assumed. Differences in opinion were resolved by consensus, assuming the most experienced reader's opinion as the definitive one. A schematic representation of each VI-RADS category is shown in Supplementary Fig. 2 .
TURBT, Re-TURBT, and histopathologic reports
All patients underwent conventional bipolar white-light TURBT within 6 wk after mpMRI at our institution. Re-TURBT was performed within 2-6 wk after initial surgery, by the same two experienced surgeons, at the scar site/sites of first resection for all T1 patients as well as for those with HG-Ta missing muscularis propria in the resection specimen. All tumor samples were analyzed by two experienced uropathologists. Outcomes from Re-TURBT reports (absence of cancer and/or persistent NMIBC vs upstaging to MIBC) were compared with the preoperative VI-RADS scores in order to assess diagnostic accuracy of mpMRI with pathologic reports (standard reference).
Statistical analysis
To assess the performance of mpMRI in differentiating between NMIBC and MIBC (aim I), sensitivity, specificity, positive (PPV) and negative (NPV) predictive values were calculated for the whole cohort of patients who underwent mpMRI before TURBT, using TURBT for LR-NMIBC, Re-TURBT for HR-NMIBC, and RC for MIBC results as standard of reference. The performance of mpMRI was assessed by means of receiver operating characteristic (ROC) curve analysis. Inter-reader agreement analysis was performed with K statistics in order to investigate variability [ ( F i g . _ 2 ) T D $ F I G ] performance in mpMRI reading. To evaluate intrareader agreement, each reader randomly reviewed a subset of images (one-fourth of patients in each pathologic T-stage category) within 3 mo from the end of enrollment. As for secondary outcome, sensitivity, specificity, PPV, and NPV were calculated for the use of mpMRI for HR-NMIBC patients undergoing Re-TURBT. Final diagnosis after TURBT, Re-TURBT, and/or RC was considered the gold standard for detecting MIBC. ROC analysis was also performed.
All statistical analysis was performed by using software MedCalc (version 15.6.1; MedCalc Software bvba, Ostend, Belgium). All tests were two sided, and statistical significance was set at <0.05.
Results
Overall 288 patients with a primary suspicion of BCa were prospectively enrolled. Out of these, 52 (18%) cases did not meet the inclusion criteria and were consequently excluded from further evaluation ( Fig. 1 TURBT showed sensitivity and specificity of 85% (95% CI: 62. 
Discussion
BCa prognosis and management mostly reflect tumor stage at primary diagnosis. The VI-RADS scoring system has been developed with the intent of standardizing staging, diagnosis, and eventually in future therapeutic response, through a consensus-driven approach to reproducible imaging and reporting.
[ ( F i g . _ 3 ) T D $ F I G ] Clinical application of preoperative VI-RADS score for NMIBC versus MIBC discrimination at primary resection has been validated recently, with good diagnostic accuracy by different groups. First, Barchetti et al [17] in a retrospective series reported significant diagnostic outcomes in MIBC discrimination confirmed at TURBT with a good interreader agreement between two experienced genitourinary radiologists (AUC 0.92 and 0.87 for readers 1 and 2, respectively; Ƙ = 0.73). In addition, Ueno et al [18] definitively confirmed the excellent performance with fine reproducibility of VI-RADS score in muscle-invasive tissue detection with an intraclass correlation coefficient of 0.85 (95% CI:0.8-0.89) among five different readers, achieving high diagnostic performance represented by a pooled AUC of 0.90 (95% CI: 0.87-0.93). To date, the most recent and large retrospective validation of VI-RADS criterion >2 for MIBC detection was published by Wang et al [19] . The authors demonstrated high diagnostic performance (AUC of 0.94) and the highest inter-reader agreement ever reported (Ƙ = 0.92). These studies, therefore, have to be considered the initial evidence testifying clinical reliability of VI-RADS as a pre-TURBT tool to identify patients suffering from MIBC. However, their retrospective nature and single-center design should be advocated as the primary limitation. To our knowledge, our study represents the first large prospective analysis demonstrating high diagnostic reli-ability of VI-RADS score, specifically cutoff 1-2 versus 3-5, in differentiating superficial from invasive disease at TURBT (sensitivity 91.9%, 95% CI: 82.2-97.3; specificity 91.1%, 95% CI: 85.8-94.9; PPV 77.5%, 95% CI: 65.8-86.7; NPV 97.1%, 95% CI: 93.3-99.1; inter-reader Ƙ = 0.81, 95% CI: 0.65-0.93).
Our assessed secondary aim has to be considered a future ambitious perspective analyzing the applicability of VI-RADS score in the management of patients diagnosed with HR-NMIBC at TURBT, who, in the majority of cases, are currently candidate for Re-TURBT.
A number of quality issues, some potentially linked to the experience of the surgeon, indeed suggest that the initial TURBT may be inadequate in a high percent of these patients, with residual tumor rates varying between 33% and 76% for all the cases, achieving 27-72% and 33-78% for Ta and T1 tumors, respectively. Even more strikingly, underestimation of tumor depth invasion at first TURBT has been evidenced in up to 7-30% of cases, increasing up to 45-51% in those with HG-T1 tumors undergoing RC or in those where no muscle was detected in the specimen after initial resection [20, 21] .
As nicely advocated by Babjuk [22] , Re-TURBT should therefore be considered an "emergency rescue" performed because of the uncertain quality of the first TURBT. However, this early repeated resection is not devoid of relevant and severe intra-and/or postoperative complications together with significant socioeconomic implications and health-care-related costs [23, 24] .
Among available studies present in literature, none have based their findings on any preoperative/intraoperative tool for the identification of the ideal Re-TURBT HR-NMIBC candidate. In a large retrospective series, Angulo et al [25] basically demonstrated that performing Re-TUR did not impact long-term progression-free and disease-specific survival (hazard ratio [HR] = 0.77, 95% CI: 0.6-1.7; p = 0.9 and HR = 1.46, 95% CI:0.8-2.6; p = 0.21, respectively). Another large prospective randomized study from the Nordic Association of Urology [26] revealed that tumor status at repeat TUR had a marginal role in influencing long-term cancer-specific survival (CSS; HR = 2.32, 95% CI: 0.7-7.74, p = 0.16 and HR = 3.03, 95% CI: 0.89-10.34, p = 0.07 for high-risk Ta and T1, respectively). Interestingly, Gontero et al [27] demonstrated, when stratifying patients according to presence/absence of detrusor muscle at TURBT, how the impact of Re-TURBT had only borderline effect on CSS (HR = 0.31, 95% CI: 0.09-1.08, p = 0.07) for those with absence of muscularis propria in the resection specimen. Even more surprisingly, in those cases with muscle included in the TURBT specimen, Re-TURBT either did not improve or only slightly improved CSS and OS (CSS, HR = 1.6, 95% CI: 1.11-2.31, p = 0.01; OS, HR = 1.23, 95% CI: 0.97-1.56, p = 0.09).
In our cohort of HR-NMIBC patients, we demonstrated a good concordance in discriminating the absence of cancer/ persistent NMIBC versus upstaging to MIBC at Re-TURBT (sensitivity and specificity: 85%, 95% CI: 62.1-96.8 and 93.6%, 95% CI: 86.6-97.6, respectively; PPV and NPV: 74.5%, 95% CI: 52.4-90.1 and 96.6%, 95% CI: 90.5-99.3, respectively), confirming our hypothesis of VI-RADS score as an interesting potential predictor of adverse pathology at Re-TURBT. Even if cases on adequate concordance between VI-RADS 1-2 and absence of MIBC at Re-TURBT (n = 94, 82.4%) were quantitatively more significant than those on concordance between VI-RADS 3-5 and detection of understaged disease at Re-TURBT (n = 20, 17.5%), we still should be cautious advocating mpMRI as a predictive criterion for the selection of patients who could eventually avoid Re-TURBT. This is also due to the significant rate of persistence of NMIBC detected at Re-TURBT in our series (n = 36, 31.5%). These findings are in line with the available literature confirming the pitfalls of initial TURB in providing complete eradication of BCa in HR-NMIBC patients. Different experience analyzing new intraoperative imaging methods such as photodynamic diagnosis (PDD) has shown a reduction in the rate of persistent disease down to 15% of cases [28, 29] . A future combined approach of mpMRI imaging and PDD-TURBT may improve preoperative detection and intraoperative resection of bladder neoplasms, potentially reducing the need for early restaging procedures.
Despite promising outcomes, our series is not devoid of limitations. First and more importantly, diagnosis of CIS cannot be made with imaging methods; therefore, mpMRI cannot be adopted yet for this large portion of per-definition high-risk cases. Second, although our results are prospective, these were obtained with a small-sized, single-center sample, leading to all our MRI acquisitions being achieved by the same highly performing 3 T magnet and making applicability of our results to clinical routine slightly difficult. At this point, large multicenter randomized experience has been acknowledged as the remaining step before assuming VI-RADS as a standardized, reliable, reproducible, and highly performing preoperative tool for BCa staging.
Finally, even though we are not hiding our enthusiasm for future clinical applications of mpMRI and VI-RADS score for BCa management, their role as a diagnostic tool for patients candidate for Re-TURBT still need to be confirmed. In addition, we admit that we are still far from avoiding unnecessary secondary resections. However, mpMRI of the bladder might be considered for future predictive models in order to assess the risk of understaged MIBC after first resection, thus improving adequate diagnosis and prognosis of this large proportion of bladder tumors.
Conclusions
VI-RADS score is a novel imaging tool leading urologist to properly differentiate patients with superficial or muscleinvasive disease before TURBT. In this study, we tested the ability of VI-RADS score 2 as a clinical predictor of noninvasive disease at Re-TURBT. Improvement of the diagnostic performance of mpMRI and of the quality issues of primary TURBT will be mandatory prior to consider VI-RADS as a reliable stratification tool for patients candidate for avoiding early repeated resection. At the same time, we tested the VI-RADS cutoff of 3 as a predictor of understaged MIBC at TURBT with the intent for future identification of false-negative cases that should definitely not miss repeated resection of the primary tumor site. 
